• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Brolucizumab results and adverse visual outcomes study: A single-center real-world Indian experience.

作者信息

Venkatesh Ramesh, Kathare Rupal, Jayadev Chaitra, Prabhu Vishma, Gadde Santosh Gopi Krishna, Yadav Naresh Kumar

机构信息

Department of Retina and Vitreous, Narayana Nethralaya, Rajaji Nagar, Bengaluru, Karnataka, India.

出版信息

Indian J Ophthalmol. 2025 Jun 1;73(6):921-923. doi: 10.4103/IJO.IJO_1897_24. Epub 2025 May 28.

DOI:10.4103/IJO.IJO_1897_24
PMID:40434468
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12178355/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf63/12178355/753084fb1859/IJO-73-921-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf63/12178355/753084fb1859/IJO-73-921-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf63/12178355/753084fb1859/IJO-73-921-g001.jpg

相似文献

1
Brolucizumab results and adverse visual outcomes study: A single-center real-world Indian experience.布罗利尤单抗疗效及不良视力结局研究：一项单中心印度真实世界经验
Indian J Ophthalmol. 2025 Jun 1;73(6):921-923. doi: 10.4103/IJO.IJO_1897_24. Epub 2025 May 28.
2
Short-Term Treatment Outcomes of Brolucizumab in Patients with Neovascular Age-Related Macular Degeneration: A Multicentre Indian Real-World Evidence Study.布罗鲁单抗治疗新生血管性年龄相关性黄斑变性患者的短期治疗结果：一项印度多中心真实世界证据研究。
Clin Ophthalmol. 2023 Aug 10;17:2295-2307. doi: 10.2147/OPTH.S415044. eCollection 2023.
3
Brolucizumab in Neovascular Age-Related Macular Degeneration - Indian Real-World Experience: The BRAILLE Study.布罗鲁单抗治疗新生血管性年龄相关性黄斑变性——印度真实世界经验：BRAILLE研究
Clin Ophthalmol. 2021 Sep 7;15:3787-3795. doi: 10.2147/OPTH.S328160. eCollection 2021.
4
Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario - The BRADIR study.在印度真实世界场景中，布罗利珠单抗与阿柏西普治疗顽固性糖尿病性黄斑水肿的比较——BRADIR研究
Am J Ophthalmol Case Rep. 2024 Aug 23;36:102152. doi: 10.1016/j.ajoc.2024.102152. eCollection 2024 Dec.
5
Safety and effectiveness of brolucizumab in patients with neovascular age-related macular degeneration: A phase IV study from India.布罗利珠单抗治疗新生血管性年龄相关性黄斑变性患者的安全性和有效性：一项来自印度的IV期研究。
Indian J Ophthalmol. 2025 Jun 1;73(6):826-832. doi: 10.4103/IJO.IJO_1914_24. Epub 2025 Apr 17.
6
Brolucizumab in Neovascular Age-Related Macular Degeneration - Indian Real-World Experience: The BRAILLE Study - Fifty-Two-Week Outcomes.布罗鲁单抗治疗新生血管性年龄相关性黄斑变性——印度真实世界经验：BRAILLE研究——52周结果
Clin Ophthalmol. 2022 Dec 23;16:4303-4313. doi: 10.2147/OPTH.S395577. eCollection 2022.
7
Two-Years Real-World Experience of a Tertiary Center with Intravitreal Brolucizumab Switch for Treatment of Exudative Neovascular Age-Related Macular Degeneration.三级医疗中心使用玻璃体内注射布罗芦izumab转换疗法治疗渗出性年龄相关性黄斑变性的两年真实世界经验
Ophthalmol Ther. 2025 Jun;14(6):1325-1335. doi: 10.1007/s40123-025-01141-y. Epub 2025 Apr 18.
8
Reinjection in Patients with Intraocular Inflammation Development after Intravitreal Brolucizumab Injection.玻璃体内注射布罗鲁单抗后发生眼内炎的患者再次注射情况。
Korean J Ophthalmol. 2025 Jun;39(3):213-221. doi: 10.3341/kjo.2024.0125. Epub 2025 Apr 16.
9
Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: A real-world case series.玻璃体内注射布罗珠单抗治疗顽固性糖尿病性黄斑水肿的超说明书应用：一项真实世界病例系列研究
Am J Ophthalmol Case Rep. 2021 Sep 1;24:101197. doi: 10.1016/j.ajoc.2021.101197. eCollection 2021 Dec.
10
First-year real-world experience of intravitreal brolucizumab injection for refractory neovascular age-related macular degeneration.玻璃体内注射布罗珠单抗治疗难治性新生血管性年龄相关性黄斑变性的第一年真实世界经验。
Jpn J Ophthalmol. 2025 Jan;69(1):43-48. doi: 10.1007/s10384-024-01134-7. Epub 2024 Nov 5.

本文引用的文献

1
Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group.由 VRSI 研究小组报告的印度患者中与 brolucizumab 相关的眼内炎症。
Indian J Ophthalmol. 2024 Aug 1;72(8):1156-1161. doi: 10.4103/IJO.IJO_2973_23. Epub 2024 Jul 29.
2
Factors Associated With Intraocular Inflammation in Neovascular Age-Related Macular Degeneration Patients Treated With Brolucizumab.与接受 Brolucizumab 治疗的新生血管性年龄相关性黄斑变性患者眼内炎症相关的因素。
Invest Ophthalmol Vis Sci. 2024 Jan 2;65(1):8. doi: 10.1167/iovs.65.1.8.
3
INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN: A Multicenter Age-Related Macular Degeneration Study.
日本博鲁力单抗治疗后眼内炎症的发生率和危险因素：一项多中心年龄相关性黄斑变性研究。
Retina. 2024 Apr 1;44(4):714-722. doi: 10.1097/IAE.0000000000004009.
4
KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema.KESTREL 和 KITE 第 3 阶段研究：康柏西普治疗糖尿病黄斑水肿患者的 100 周结果。
Am J Ophthalmol. 2024 Apr;260:70-83. doi: 10.1016/j.ajo.2023.07.012. Epub 2023 Jul 15.
5
RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence.康柏西普治疗新生血管性年龄相关性黄斑变性后发生视网膜血管炎或血管阻塞：真实世界证据的系统评价。
Retina. 2023 Jul 1;43(7):1051-1063. doi: 10.1097/IAE.0000000000003769. Epub 2023 Jun 16.
6
Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map.Brolucizumab 治疗新生血管性年龄相关性黄斑变性的安全性结局：IRIS 注册研究和 Komodo 医疗保健地图的结果。
JAMA Ophthalmol. 2022 Jan 1;140(1):20-28. doi: 10.1001/jamaophthalmol.2021.4585.
7
Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.Brolucizumab 相关炎症、视网膜血管炎和视网膜阻塞相关事件的风险：HAWK 和 HARRIER 的事后回顾。
Ophthalmology. 2021 Jul;128(7):1050-1059. doi: 10.1016/j.ophtha.2020.11.011. Epub 2020 Nov 15.
8
HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.HAWK和HARRIER：布罗鲁单抗治疗新生血管性年龄相关性黄斑变性3期试验的96周结果
Ophthalmology. 2021 Jan;128(1):89-99. doi: 10.1016/j.ophtha.2020.06.028. Epub 2020 Jun 20.
9
Brolucizimab-leading an era of structural revolution for long-term VEGF suppression.布罗鲁单抗——引领长期抑制血管内皮生长因子的结构革命时代。
Eye (Lond). 2020 Apr;34(4):611-613. doi: 10.1038/s41433-019-0583-z. Epub 2019 Sep 19.
10
scFv antibody: principles and clinical application.单链抗体片段：原理与临床应用
Clin Dev Immunol. 2012;2012:980250. doi: 10.1155/2012/980250. Epub 2012 Mar 15.